Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: outer membrane protein targeting antibiotics - Basilea Pharmaceutica

Drug Profile

Research programme: outer membrane protein targeting antibiotics - Basilea Pharmaceutica

Alternative Names: OMPTA - Spexis; OMPTA BamA program - Spexis; Outer membrane protein targeting antibiotics - Spexis; PEM - Spexis; POL 7001; POL-0067; POL-6137; Protein epitope mimetic molecules - Spexis

Latest Information Update: 16 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Polyphor; University of Zurich
  • Developer Basilea Pharmaceutica
  • Class Antibacterials; Cyclic peptides; Epitopes; Macrocyclic compounds; Peptidomimetics
  • Mechanism of Action Bacterial outer membrane protein modulators; Imp protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Gram-negative infections

Most Recent Events

  • 15 Jan 2024 Basilea Pharmaceutica acquires antibacterials research programme from Spexis
  • 07 Jun 2023 Antibacterial research programme is still in preclinical phase for Gram negative infections in Switzerlands
  • 07 Jun 2023 Pharmacodynamics, adverse events and antimicrobial data from preclinical trial in Gram-negative infections released by Spexis
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top